Table 4.
Comparison of pretreatment factors between groups of patients with high neutrophil-to-lymphocyte ratio (>3.21) and low neutrophil-to-lymphocyte ratio (≤3.21).
| Characteristics | Patients with High NLR (n = 15) | Patients with Low NLR (n = 24) | p Value |
|---|---|---|---|
| Age (years) | 68.6 (6.54) | 69.7 (7.41) | 0.671 |
| Sex (male/female) | 13/2 | 21/3 | 0.940 |
| Etiology (viral/non-viral) | 8/7 | 11/13 | 0.649 |
| BCLC stage (B/C) | 8/7 | 13/11 | 0.960 |
| Treatment history with MTA (yes/no) | 10/5 | 14/10 | 0.603 |
| Aspartate aminotransferase (IU/L) | 51.5 (40.0) | 51.0 (36.6) | 0.762 |
| Alanine aminotransferase (IU/L) | 38.0 (24.8) | 37.8 (25.1) | 0.977 |
| Platelets (×104/μL) | 16.4 (5.45) | 14.7 (5.90) | 0.411 |
| Child-Pugh score (5A/6A or 7B) | 8/7 | 17/7 | 0.268 |
| ALBI score | −2.32 (0.40) | −2.48 (0.39) | 0.298 |
| modified ALBI grade (1/2a or 2b) | 5/10 | 10/14 | 0.603 |
| α-fetoprotein (ng/mL) | 6235 (14969) | 1584 (5503) | 0.387 |
| Des-γ-carboxy prothrombin (mAU/mL) | 14695 (47306) | 5999 (24510) | 0.312 |
| FIB-4 index | 3.88 (2.39) | 4.83 (3.08) | 0.488 |
| Neutrophil-to-lymphocyte ratio (NLR) | 4.97 (2.69) | 2.00 (0.67) | <0.0001 |
| Platelet-to-lymphocyte ratio (PLR) | 193 (77.3) | 113 (38.5) | 0.002 |
| Lymphocyte-to-monocyte ratio (LMR) | 2.27 (1.20) | 3.13 (1.05) | 0.021 |
Values are presented as mean (standard deviation) or number. NLR, neutrophil-to-lymphocyte ratio; BCLC, Barcelona Clinic Liver Cancer; MTA, molecular-targeted agent; ALBI, albumin-bilirubin; AU, arbitrary unit; FIB-4, fibrosis-4.